CCCTC-binding factor acts as a heterochromatin barrier on herpes simplex viral latent chromatin and contributes to poised latent infection

mBio

Volumn 9, Issue 1, 2018, Pages

  Lee, Jennifer S ^a,b   Raja, Priya ^a   Pan, Dongli ^a,c   Pesola, Jean M ^a   Coen, Donald M ^a   Knipe, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Oncorus Inc   (United States)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chromatin; Epigenetics; Herpes simplex virus; Latent infection; Regulation of gene expression

Indexed keywords

TRANSCRIPTION FACTOR CTCF; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL MODIFICATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; DELETION MUTANT; EPIGENETICS; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HETEROCHROMATIN; ICP0 GENE; INTRON; LAT GENE; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; VIRUS GENE; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANIMAL; CHLOROCEBUS AETHIOPS; CHROMATIN; DISEASE MODEL; GENETICS; HELA CELL LINE; HERPES SIMPLEX; HOST PATHOGEN INTERACTION; HUMAN; HUMAN ALPHAHERPESVIRUS 1; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; VERO CELL LINE; VIROLOGY; VIRUS ACTIVATION;

ANIMALS; BINDING SITES; CCCTC-BINDING FACTOR; CERCOPITHECUS AETHIOPS; CHROMATIN; DISEASE MODELS, ANIMAL; DNA, VIRAL; HELA CELLS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTATION; VERO CELLS; VIRUS ACTIVATION;

EID: 85043524916     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02372-17     Document Type: Article

References (88)

1. Roizman B, Knipe DM, Whitley RJ. 2013. Herpes simplex viruses, p 1823–1897. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Knipe DM, Cliffe A. 2008. Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Microbiol 6:211–221. https://doi.org/10.1038/nrmicro1794.
3. Knipe DM, Lieberman PM, Jung JU, McBride AA, Morris KV, Ott M, Margolis D, Nieto A, Nevels M, Parks RJ, Kristie TM. 2013. Snapshots: chromatin control of viral infection. Virology 435:141–156. https://doi.org/10.1016/j.virol.2012.09.023.
4. Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. 1987. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science 235:1056–1059. https://doi.org/10.1126/science.2434993.
5. Kramer MF, Coen DM. 1995. Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol 69:1389–1399.
6. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. 2008. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 454:780–783. https://doi.org/10.1038/nature07103.
7. Umbach JL, Nagel MA, Cohrs RJ, Gilden DH, Cullen BR. 2009. Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. J Virol 83:10677–10683. https://doi.org/10.1128/JVI.01185-09.
8. Jurak I, Kramer MF, Mellor JC, van Lint AL, Roth FP, Knipe DM, Coen DM. 2010. Numerous conserved and divergent microRNAs expressed by herpes simplex viruses 1 and 2. J Virol 84:4659– 4672. https://doi.org/10.1128/JVI.02725-09.
9. Deshmane SL, Fraser NW. 1989. During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J Virol 63:943–947.
10. Garber DA, Schaffer PA, Knipe DM. 1997. A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1. J Virol 71: 5885–5893.
11. Chen SH, Kramer MF, Schaffer PA, Coen DM. 1997. A viral function represses accumulation of transcripts from productive-cycle genes in mouse ganglia latently infected with herpes simplex virus. J Virol 71: 5878–5884.
12. Leib DA, Bogard CL, Kosz-Vnenchak M, Hicks KA, Coen DM, Knipe DM, Schaffer PA. 1989. A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J Virol 63:2893–2900.
13. Javier RT, Stevens JG, Dissette VB, Wagner EK. 1988. A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state. Virology 166:254–257. https://doi.org/10.1016/0042-6822(88)90169-9.
14. Steiner I, Spivack JG, Lirette RP, Brown SM, MacLean AR, Subak-Sharpe JH, Fraser NW. 1989. Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection. EMBO J 8:505–511.
15. Nicoll MP, Hann W, Shivkumar M, Harman LE, Connor V, Coleman HM, Proença JT, Efstathiou S. 2016. The HSV-1 latency-associated transcript functions to repress latent phase lytic gene expression and suppress virus reactivation from latently infected neurons. PLoS Pathog 12:e1005539. https://doi.org/10.1371/journal.ppat.1005539.
16. Drolet BS, Perng GC, Cohen J, Slanina SM, Yukht A, Nesburn AB, Wechsler SL. 1998. The region of the herpes simplex virus type 1 LAT gene involved in spontaneous reactivation does not encode a functional protein. Virology 242:221–232. https://doi.org/10.1006/viro.1997.9020.
17. Tang S, Bertke AS, Patel A, Wang K, Cohen JI, Krause PR. 2008. An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. Proc Natl Acad Sci U S A 105:10931–10936. https://doi.org/10.1073/pnas.0801845105.
18. Flores O, Nakayama S, Whisnant AW, Javanbakht H, Cullen BR, Bloom DC. 2013. Mutational inactivation of herpes simplex virus 1 microRNAs identifies viral mRNA targets and reveals phenotypic effects in culture. J Virol 87:6589– 6603. https://doi.org/10.1128/JVI.00504-13.
19. Jiang X, Chentoufi AA, Hsiang C, Carpenter D, Osorio N, BenMohamed L, Fraser NW, Jones C, Wechsler SL. 2011. The herpes simplex virus type 1 latency-associated transcript can protect neuron-derived C1300 and Neuro2A cells from granzyme B-induced apoptosis and CD8 T-cell killing. J Virol 85:2325–2332. https://doi.org/10.1128/JVI.01791-10.
20. Cliffe AR, Coen DM, Knipe DM. 2013. Kinetics of facultative heterochromatin and Polycomb group protein association with the herpes simplex viral genome during establishment of latent infection. mBio 4:e00590 -12. https://doi.org/10.1128/mBio.00590-12.
21. Wang QY, Zhou C, Johnson KE, Colgrove RC, Coen DM, Knipe DM. 2005. Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection. Proc Natl Acad Sci U S A 102:16055–16059. https://doi.org/10.1073/pnas.0505850102.
22. Kwiatkowski DL, Thompson HW, Bloom DC. 2009. The Polycomb group protein Bmi1 binds to the herpes simplex virus 1 latent genome and maintains repressive histone marks during latency. J Virol 83:8173– 8181. https://doi.org/10.1128/JVI.00686-09.
23. Cliffe AR, Garber DA, Knipe DM. 2009. Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters. J Virol 83:8182– 8190. https://doi.org/10.1128/JVI.00712-09.
24. Dobson AT, Sederati F, Devi-Rao G, Flanagan J, Farrell MJ, Stevens JG, Wagner EK, Feldman LT. 1989. Identification of the latency-associated transcript promotor by expression of rabbit beta-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus. J Virol 65:3844–3851.
25. Lokensgard JR, Bloom DC, Dobson AT, Feldman LT. 1994. Long-term promoter activity during herpes simplex virus latency. J Virol 68: 7148–7158.
26. Lokensgard JR, Berthomme H, Feldman LT. 1997. The latency-associated promoter of herpes simplex virus type 1 requires a region downstream of the transcription start site for long-term expression during latency. J Virol 71:6714– 6719.
27. Batchelor AH, O’Hare P. 1990. Regulation and cell-type-specific activity of a promoter located upstream of the latency-associated transcript of herpes simplex virus type 1. J Virol 64:3269–3279.
28. Zwaagstra JC, Ghiasi H, Slanina SM, Nesburn AB, Wheatley SC, Lillycrop K, Wood J, Latchman DS, Patel K, Wechsler SL. 1990. Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol 64:5019–5028.
29. Spivack JG, Fraser NW. 1988. Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection. J Virol 62:1479–1485.
30. Amelio AL, Giordani NV, Kubat NJ, O’Neil JE, Bloom DC. 2006. Deacety-lation of the herpes simplex virus type 1 latency-associated transcript (LAT) enhancer and a decrease in LAT abundance precede an increase in ICP0 transcriptional permissiveness at early times postexplant. J Virol 80:2063–2068. https://doi.org/10.1128/JVI.80.4.2063-2068.2006.
31. Kosz-Vnenchak M, Jacobson J, Coen DM, Knipe DM. 1993. Evidence for a novel regulatory pathway for herpes simplex virus gene expression in trigeminal ganglion neurons. J Virol 67:5383–5393.
32. Devi-Rao GB, Bloom DC, Stevens JG, Wagner EK. 1994. Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia. J Virol 68:1271–1282.
33. Chen J, Silverstein S. 1992. Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression. J Virol 66:2916–2927.
34. Cai W, Schaffer PA. 1992. Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells. J Virol 66:2904–2915.
35. Orzalli MH, DeLuca NA, Knipe DM. 2012. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc Natl Acad Sci U S A 109:E3008–E3017. https://doi.org/10.1073/pnas.1211302109.
36. Orzalli MH, Conwell SE, Berrios C, Decaprio JA, Knipe DM. 2013. Nuclear interferon-inducible protein 16 promotes silencing of herpesviral and transfected DNA. Proc Natl Acad Sci U S A 110:E4492–E4501. https://doi.org/10.1073/pnas.1316194110.
37. Chelbi-Alix MK, de Thé H. 1999. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18:935–941. https://doi.org/10.1038/sj.onc.1202366.
38. Everett RD, Murray J. 2005. ND10 components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection. J Virol 79:5078–5089. https://doi.org/10.1128/JVI.79.8.5078-5089.2005.
39. Jurak I, Silverstein LB, Sharma M, Coen DM. 2012. Herpes simplex virus is equipped with RNA- and protein-based mechanisms to repress expression of ATRX, an effector of intrinsic immunity. J Virol 86: 10093–10102. https://doi.org/10.1128/JVI.00930-12.
40. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A. 2006. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 80:7995– 8005. https://doi.org/10.1128/JVI.00734-06.
41. Gu H, Liang Y, Mandel G, Roizman B. 2005. Components of the REST/ CoREST/histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells. Proc Natl Acad Sci U S A 102:7571–7576. https://doi.org/10.1073/pnas.0502658102.
42. Gu H, Roizman B. 2007. Herpes simplex virus-infected cell protein 0 blocks the silencing of viral DNA by dissociating histone deacetylases from the CoREST-REST complex. Proc Natl Acad Sci U S A 104:17134–17139. https://doi.org/10.1073/pnas.0707266104.
43. Proença JT, Coleman HM, Connor V, Winton DJ, Efstathiou S. 2008. A historical analysis of herpes simplex virus promoter activation in vivo reveals distinct populations of latently infected neurones. J Gen Virol 89:2965–2974. https://doi.org/10.1099/vir.0.2008/005066-0.
44. Raja P, Lee JS, Pan D, Pesola JM, Coen DM, Knipe DM. 2016. A herpesviral lytic protein regulates the structure of latent viral chromatin. mBio 7:e00633-16. https://doi.org/10.1128/mBio.00633-16.
45. Lobanenkov VV, Nicolas RH, Adler VV, Paterson H, Klenova EM, Po-lotskaja AV, Goodwin GH. 1990. A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5′-flanking sequence of the chicken c-myc gene. Oncogene 5:1743–1753.
46. Baniahmad A, Steiner C, Köhne AC, Renkawitz R. 1990. Modular structure of a chicken lysozyme silencer: involvement of an unusual thyroid hormone receptor binding site. Cell 61:505–514. https://doi.org/10.1016/0092-8674(90)90532-J.
47. Lobanenkov VV, Gudvin GG. 1989. CCCTC-binding protein: a new nuclear protein factor which interaction with 5′-flanking sequence of chicken c-myc oncogene correlates with repression of the gene. Dokl Akad Nauk SSSR 309:741–745.
48. Köhne AC, Baniahmad A, Renkawitz R. 1993. NeP1. A ubiquitous transcription factor synergizes with v-ERBA in transcriptional silencing. J Mol Biol 232:747–755. https://doi.org/10.1006/jmbi.1993.1428.
49. Klenova EM, Nicolas RH, Paterson HF, Carne AF, Heath CM, Goodwin GH, Neiman PE, Lobanenkov VV. 1993. CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol 13:7612–7624. https://doi.org/10.1128/MCB.13.12.7612.
50. Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G, Neiman PE, Collins SJ, Lobanenkov VV. 1996. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 16:2802–2813. https://doi.org/10.1128/MCB.16.6.2802.
51. Bell AC, West AG, Felsenfeld G. 1999. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98:387–396. https://doi.org/10.1016/S0092-8674(00)81967-4.
52. Fu Y, Sinha M, Peterson CL, Weng Z. 2008. The insulator binding protein CTCF positions 20 nucleosomes around its binding sites across the human genome. PLoS Genet 4:e1000138. https://doi.org/10.1371/journal.pgen.1000138.
53. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R, Oberdoerffer S. 2011. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 479: 74–79. https://doi.org/10.1038/nature10442.
54. Splinter E, Heath H, Kooren J, Palstra RJ, Klous P, Grosveld F, Galjart N, de Laat W. 2006. CTCF mediates long-range chromatin looping and local histone modification in the beta-globin locus. Genes Dev 20:2349–2354. https://doi.org/10.1101/gad.399506.
55. Handoko L, Xu H, Li G, Ngan CY, Chew E, Schnapp M, Lee CW, Ye C, Ping JL, Mulawadi F, Wong E, Sheng J, Zhang Y, Poh T, Chan CS, Kunarso G, Shahab A, Bourque G, Cacheux-Rataboul V, Sung WK, Ruan Y, Wei CL. 2011. CTCF-mediated functional chromatin interactome in pluripotent cells. Nat Genet 43:630– 638. https://doi.org/10.1038/ng.857.
56. Ong CT, Corces VG. 2014. CTCF: an architectural protein bridging genome topology and function. Nat Rev Genet 15:234–246. https://doi.org/10.1038/nrg3663.
57. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. 2000. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/ Igf2 locus. Nature 405:486–489. https://doi.org/10.1038/35013106.
58. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, Zhang MQ, Lobanenkov VV, Ren B. 2007. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 128: 1231–1245. https://doi.org/10.1016/j.cell.2006.12.048.
59. Chung JH, Whiteley M, Felsenfeld G. 1993. A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 74:505–514. https://doi.org/10.1016/0092-8674(93)80052-G.
60. Tempera I, Wiedmer A, Dheekollu J, Lieberman PM. 2010. CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog 6:e1001048. https://doi.org/10.1371/journal.ppat.1001048.
61. Stedman W, Kang H, Lin S, Kissil JL, Bartolomei MS, Lieberman PM. 2008. Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators. EMBO J 27:654– 666. https://doi.org/10.1038/emboj.2008.1.
62. Kang H, Wiedmer A, Yuan Y, Robertson E, Lieberman PM. 2011. Coordination of KSHV latent and lytic gene control by CTCF-cohesin mediated chromosome conformation. PLoS Pathog 7:e1002140. https://doi.org/10.1371/journal.ppat.1002140.
63. Martínez FP, Cruz R, Lu F, Plasschaert R, Deng Z, Rivera-Molina YA, Bartolomei MS, Lieberman PM, Tang Q. 2014. CTCF binding to the first intron of the major immediate early (MIE) gene of human cytomegalo-virus (HCMV) negatively regulates MIE gene expression and HCMV replication. J Virol 88:7389–7401. https://doi.org/10.1128/JVI.00845-14.
64. Amelio AL, McAnany PK, Bloom DC. 2006. A chromatin insulator-like element in the herpes simplex virus type 1 latency-associated transcript region binds CCCTC-binding factor and displays enhancer-blocking and silencing activities. J Virol 80:2358–2368. https://doi.org/10.1128/JVI.80.5.2358-2368.2006.
65. Chen Q, Lin L, Smith S, Huang J, Berger SL, Zhou J. 2007. CTCF-dependent chromatin boundary element between the latency-associated transcript and ICP0 promoters in the herpes simplex virus type 1 genome. J Virol 81:5192–5201. https://doi.org/10.1128/JVI.02447-06.
66. Ertel MK, Cammarata AL, Hron RJ, Neumann DM. 2012. CTCF occupation of the herpes simplex virus 1 genome is disrupted at early times postreacti-vation in a transcription-dependent manner. J Virol 86:12741–12759. https://doi.org/10.1128/JVI.01655-12.
67. Harkness JM, Kader M, DeLuca NA. 2014. Transcription of the herpes simplex virus 1 genome during productive and quiescent infection of neuronal and nonneuronal cells. J Virol 88:6847– 6861. https://doi.org/10.1128/JVI.00516-14.
68. Lang F, Li X, Vladimirova O, Hu B, Chen G, Xiao Y, Singh V, Lu D, Li L, Han H, Wickramasinghe JM, Smith ST, Zheng C, Li Q, Lieberman PM, Fraser NW, Zhou J. 2017. CTCF interacts with the lytic HSV-1 genome to promote viral transcription. Sci Rep 7:39861. https://doi.org/10.1038/srep39861.
69. Kramer MF, Jurak I, Pesola JM, Boissel S, Knipe DM, Coen DM. 2011. Herpes simplex virus 1 microRNAs expressed abundantly during latent infection are not essential for latency in mouse trigeminal ganglia. Virology 417:239–247. https://doi.org/10.1016/j.virol.2011.06.027.
70. Kubat NJ, Amelio AL, Giordani NV, Bloom DC. 2004. The herpes simplex virus type 1 latency-associated transcript (LAT) enhancer/rcr is hyper-acetylated during latency independently of LAT transcription. J Virol 78:12508–12518. https://doi.org/10.1128/JVI.78.22.12508-12518.2004.
71. Kubat NJ, Tran RK, McAnany P, Bloom DC. 2004. Specific histone tail modification and not DNA methylation is a determinant of herpes simplex virus type 1 latent gene expression. J Virol 78:1139–1149. https://doi.org/10.1128/JVI.78.3.1139-1149.2004.
72. Felsenfeld G, Burgess-Beusse B, Farrell C, Gaszner M, Ghirlando R, Huang S, Jin C, Litt M, Magdinier F, Mutskov V, Nakatani Y, Tagami H, West A, Yusufzai T. 2004. Chromatin boundaries and chromatin domains. Cold Spring Harb Symp Quant Biol 69:245–250. https://doi.org/10.1101/sqb.2004.69.245.
73. Majumder P, Boss JM. 2010. CTCF controls expression and chromatin architecture of the human major histocompatibility complex class II locus. Mol Cell Biol 30:4211–4223. https://doi.org/10.1128/MCB.00327-10.
74. Phillips JE, Corces VG. 2009. CTCF: master weaver of the genome. Cell 137:1194–1211. https://doi.org/10.1016/j.cell.2009.06.001.
75. Ohlsson R, Renkawitz R, Lobanenkov V. 2001. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17:520–527. https://doi.org/10.1016/S0168-9525(01)02366-6.
76. Chen HS, Martin KA, Lu F, Lupey LN, Mueller JM, Lieberman PM, Tempera I. 2014. Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site. J Virol 88: 1703–1713. https://doi.org/10.1128/JVI.02209-13.
77. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315–326. https://doi.org/10.1016/j.cell.2006.02.041.
78. Lesch BJ, Page DC. 2014. Poised chromatin in the mammalian germ line. Development 141:3619–3626. https://doi.org/10.1242/dev.113027.
79. Cliffe AR, Arbuckle JH, Vogel JL, Geden MJ, Rothbart SB, Cusack CL, Strahl BD, Kristie TM, Deshmukh M. 2015. Neuronal stress pathway mediating a histone methyl/phospho switch is required for herpes simplex virus reactivation. Cell Host Microbe 18:649– 658. https://doi.org/10.1016/j.chom.2015.11.007.
80. Sawtell NM, Thompson RL. 2016. De novo herpes simplex virus VP16 Expression gates a dynamic programmatic transition and sets the latent/ lytic balance during acute infection in trigeminal ganglia. PLoS Pathog 12:e1005877. https://doi.org/10.1371/journal.ppat.1005877.
81. Oti M, Falck J, Huynen MA, Zhou H. 2016. CTCF-mediated chromatin loops enclose inducible gene regulatory domains. BMC Genomics 17: 252. https://doi.org/10.1186/s12864-016-2516-6.
82. Leib DA, Coen DM, Bogard CL, Hicks KA, Yager DR, Knipe DM, Tyler KL, Schaffer PA. 1989. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol 63:759–768.
83. Halford WP, Schaffer PA. 2000. Optimized viral dose and transient im-munosuppression enable herpes simplex virus ICP0-null mutants to establish wild-type levels of latency in vivo. J Virol 74:5957–5967. https://doi.org/10.1128/JVI.74.13.5957-5967.2000.
84. Knipe DM, Raja P, Lee J. 2017. Viral gene products actively promote latent infection by epigenetic silencing mechanisms. Curr Opin Virol 23:68–74. https://doi.org/10.1016/j.coviro.2017.03.010.
85. Colgrove RC, Liu X, Griffiths A, Raja P, Deluca NA, Newman RM, Coen DM, Knipe DM. 2016. History and genomic sequence analysis of the herpes simplex virus 1 KOS and KOS1.1 sub-strains. Virology 487:215–221. https://doi.org/10.1016/j.virol.2015.09.026.
86. Tenser RB, Dunstan ME. 1979. Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion. Virology 99:417– 422. https://doi.org/10.1016/0042-6822(79)90021-7.
87. Coen DM, Irmiere AF, Jacobson JG, Kerns KM. 1989. Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168:221–231. https://doi.org/10.1016/0042-6822(89)90261-4.
88. Pan D, Flores O, Umbach JL, Pesola JM, Bentley P, Rosato PC, Leib DA, Cullen BR, Coen DM. 2014. A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency. Cell Host Microbe 15:446– 456. https://doi.org/10.1016/j.chom.2014.03.004.